Chongqing Fagen Biomedical

Chongqing Fagen Biomedical is a clinical-stage biotechnology company specializing in the development of innovative gene therapies using adeno-associated virus (AAV) vectors. The company focuses on addressing unmet medical needs in rare diseases, ophthalmology, and metabolic disorders through its proprietary AAV capsid discovery and optimization platform. Its lead program, FG-M001, is a gene therapy targeting Leber Hereditary Optic Neuropathy (LHON) caused by ND4 mutations. Fagen Biomedical integrates R&D with large-scale GMP manufacturing capabilities to accelerate the translation of genetic medicines. The company is headquartered in Chongqing International Biological City and was founded by experts in the field of AAV vectorology.